Cholangiocarcinoma — Trials

Cholangiocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

760 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 210
Recruiting: 120
Ph III recruiting: 7
Growth YoY: +17.4%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (106)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03081039	A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma	withdrawn	Phase 3	0	University of LouisvilleOTHER	1	Feb 19, 2018	clinicaltrials

Data updated 22 days agoSource updated Feb 19, 2018source: clinicaltrials